Ayan Basu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ayan Basu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Mehebubar Rahman
Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal, India
4 shared publicationsRama Prosad Goswami
Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal, India
4 shared publicationsYogiraj Ray
Associate Professor, Department of Infectious Diseases, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
3 shared publications- Aditya Kapoor
Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2 shared publications - Alok Nath
Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
2 shared publications - Anuj Ajayababu
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2 shared publications
Latest Publications
- 18 November 2026
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
An unexpected diagnosis behind a simple oral sore: asymptomatic neurosyphilis
Oral manifestations of syphilis are uncommon and may represent an important diagnostic clue. A 29-year-old man who has sex with men, newly diagnosed with human immunodeficiency virus (HIV) infection, presented with throat pain and a greyish-white plaque with surrounding erythema involving the soft palate and oropharynx. Microbiological investigations were negative while syphilis serology revealed a Venereal Disease Research Laboratory (VDRL) titre of 1:128 and reactive Treponema pallidum hemagglutination assay. The lesion resolved completely following benzathine penicillin. Despite the absence of neurological symptoms, cerebrospinal fluid (CSF) examination, prompted by a high serum VDRL titre and HIV co-infection, demonstrated lymphocytic pleocytosis, elevated protein and reactive CSF-VDRL, confirming asymptomatic neurosyphilis. This case illustrates how an isolated oral mucous patch served as an important diagnostic clue to clinically silent central nervous system involvement in selected high-risk patients.
- 18 November 2026
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
An unexpected diagnosis behind a simple oral sore: asymptomatic neurosyphilis
Oral manifestations of syphilis are uncommon and may represent an important diagnostic clue. A 29-year-old man who has sex with men, newly diagnosed with human immunodeficiency virus (HIV) infection, presented with throat pain and a greyish-white plaque with surrounding erythema involving the soft palate and oropharynx. Microbiological investigations were negative while syphilis serology revealed a Venereal Disease Research Laboratory (VDRL) titre of 1:128 and reactive Treponema pallidum hemagglutination assay. The lesion resolved completely following benzathine penicillin. Despite the absence of neurological symptoms, cerebrospinal fluid (CSF) examination, prompted by a high serum VDRL titre and HIV co-infection, demonstrated lymphocytic pleocytosis, elevated protein and reactive CSF-VDRL, confirming asymptomatic neurosyphilis. This case illustrates how an isolated oral mucous patch served as an important diagnostic clue to clinically silent central nervous system involvement in selected high-risk patients.
- 30 May 2026
- Published by SAGE Publications in Tropical Doctor
- Vol. 56 (4) , 745-748
Fascioliasis presenting as non-resolving liver abscess: Case series from eastern India
Fascioliasis is a foodborne trematode infection caused by Fasciola hepatica and Fasciola gigantica . It is caused by ingestion of undercooked aquatic vegetation containing infective stage metacercariae. Symptoms in the acute stage include fever, abdominal pain and eosinophilia and in the chronic stage symptoms of biliary obstruction or cholangitis. Very few fascioliasis cases have been reported from India. In the last 1 year, we diagnosed six cases of fascioliasis who presented with acute stage symptoms. They were diagnosed by characteristic dietary history, liver abscess on imaging and eggs of Fasciola in stool. They were successfully treated with Triclabendazole or Nitazoxanide.
- 30 May 2026
- Published by SAGE Publications in Tropical Doctor
- Vol. 56 (4) , 745-748
Fascioliasis presenting as non-resolving liver abscess: Case series from eastern India
Fascioliasis is a foodborne trematode infection caused by Fasciola hepatica and Fasciola gigantica . It is caused by ingestion of undercooked aquatic vegetation containing infective stage metacercariae. Symptoms in the acute stage include fever, abdominal pain and eosinophilia and in the chronic stage symptoms of biliary obstruction or cholangitis. Very few fascioliasis cases have been reported from India. In the last 1 year, we diagnosed six cases of fascioliasis who presented with acute stage symptoms. They were diagnosed by characteristic dietary history, liver abscess on imaging and eggs of Fasciola in stool. They were successfully treated with Triclabendazole or Nitazoxanide.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Journal of Postgraduate Medicine
- Vol. 71 (4) , 170-179
A systematic review and meta-analysis of clinical trials comparing arterolane-piperaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria
Introduction: Artemisinin combination therapy (ACT) is the World Health Organization (WHO) recommended first-line therapy for falciparum malaria. However, recent concern is ACT resistance. Arterolane-piperaquine is a synthetic alternative to ACT. Our objective was to determine the safety and efficacy of arterolane-piperaquine in comparison with artemether-lumefantrine for the treatment of falciparum malaria. Material and Methods: We conducted a systematic review and meta-analysis to determine the safety and efficacy of arterolane maleate and piperaquine phosphate for the treatment of uncomplicated falciparum malaria. We searched PubMed/MEDLINE, Cochrane Library, Google Scholar, Clinical Trials.gov and MedRxiv. Search results were screened by title, abstract, and full text before inclusion into the study. Meta-analysis of risk difference between arterolane-piperaquine and artemether-lumefantrine in regard to safety and efficacy was done using a random effects model. Results: Four randomized controlled trials (RCTs) were included. One RCT had a high risk of bias, while the other three studies had a low risk of bias. The 28-day polymerase chain reaction (PCR) corrected risk difference between the artemether-lumefantrine and arterolane-piperaquine was 0 (95% confidence interval −0.02 to 0.02), whereas the PCR uncorrected risk difference was 0.11 (95% confidence interval −0.06 to 0.27). On 42-day follow-up, the PCR uncorrected risk difference was 0.17 (95% confidence interval −0.05 to 0.38), while the PCR-corrected risk difference was 0.01 (95% confidence interval −0.01 to 0.03). Adverse effect profile was similar with risk difference of at least one adverse effect being −0.01 (95% confidence interval −0.02 to 0.00). The commonly reported adverse effects of arterolane-piperaquine were vomiting, anemia, and pain abdomen. Conclusions: Our study shows that arterolane-piperaquine is non-inferior to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria.
- 1 October 2025
- Published by Wolters Kluwer Health in Journal of Postgraduate Medicine
- Vol. 71 (4) , 170-179
Open AccessA systematic review and meta-analysis of clinical trials comparing arterolane-piperaquine vs. artemether-lumefantrine for the treatment of uncomplicated falciparum malaria
Introduction: Artemisinin combination therapy (ACT) is the World Health Organization (WHO) recommended first-line therapy for falciparum malaria. However, recent concern is ACT resistance. Arterolane-piperaquine is a synthetic alternative to ACT. Our objective was to determine the safety and efficacy of arterolane-piperaquine in comparison with artemether-lumefantrine for the treatment of falciparum malaria. Material and Methods: We conducted a systematic review and meta-analysis to determine the safety and efficacy of arterolane maleate and piperaquine phosphate for the treatment of uncomplicated falciparum malaria. We searched PubMed/MEDLINE, Cochrane Library, Google Scholar, Clinical Trials.gov and MedRxiv. Search results were screened by title, abstract, and full text before inclusion into the study. Meta-analysis of risk difference between arterolane-piperaquine and artemether-lumefantrine in regard to safety and efficacy was done using a random effects model. Results: Four randomized controlled trials (RCTs) were included. One RCT had a high risk of bias, while the other three studies had a low risk of bias. The 28-day polymerase chain reaction (PCR) corrected risk difference between the artemether-lumefantrine and arterolane-piperaquine was 0 (95% confidence interval −0.02 to 0.02), whereas the PCR uncorrected risk difference was 0.11 (95% confidence interval −0.06 to 0.27). On 42-day follow-up, the PCR uncorrected risk difference was 0.17 (95% confidence interval −0.05 to 0.38), while the PCR-corrected risk difference was 0.01 (95% confidence interval −0.01 to 0.03). Adverse effect profile was similar with risk difference of at least one adverse effect being −0.01 (95% confidence interval −0.02 to 0.00). The commonly reported adverse effects of arterolane-piperaquine were vomiting, anemia, and pain abdomen. Conclusions: Our study shows that arterolane-piperaquine is non-inferior to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria.
- 23 August 2024
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (9) , e601
Strongyloides stercoralis hyperinfection syndrome
- 23 August 2024
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (9) , e601
Strongyloides stercoralis hyperinfection syndrome
- Open Access
- 16 February 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (3) , 1017-1018
Correction to: Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial
- 16 February 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (3) , 1017-1018
Open AccessCorrection to: Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial
- Open Access
- 15 October 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (6) , 2205-2217
Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial
Introduction Universal coverage of vaccines alone cannot be relied upon to protect at-risk populations in lower- and middle-income countries against the impact of the coronavirus disease 2019 (COVID-19) pandemic and newer variants. Live vaccines, including Bacillus Calmette–Guérin (BCG), are being studied for their effectiveness in reducing the incidence and severity of COVID-19 infection. Methods In this multi-centre quadruple-blind, parallel assignment randomised control trial, 495 high-risk group adults (aged 18–60 years) were randomised into BCG and placebo arms and followed up for 9 months from the date of vaccination. The primary outcome was the difference in the incidence of COVID-19 infection at the end of 9 months. Secondary outcomes included the difference in the incidence of severe COVID-19 infections, hospitalisation rates, intensive care unit stay, oxygen requirement and mortality at the end of 9 months. The primary analysis was done on an intention-to-treat basis, while safety analysis was done per protocol. Results There was no significant difference in the incidence rates of cartridge-based nucleic acid amplification test (CB-NAAT) positive COVID-19 infection [odds ratio (OR) 1.08, 95% confidence interval (CI) 0.54–2.14] in the two groups, but the BCG arm showed a statistically significant decrease in clinically diagnosed (symptomatic) probable COVID-19 infections (OR 0.38, 95% CI 0.20–0.72). Compared with the BCG arm, significantly more patients developed severe COVID-19 pneumonia (CB-NAAT positive) and required hospitalisation and oxygen in the placebo arm (six versus none; p = 0.03). One patient belonging to the placebo arm required intensive care unit (ICU) stay and died. BCG had a protective efficacy of 62% (95% CI 28–80%) for likely symptomatic COVID-19 infection. Conclusions BCG is protective in reducing the incidence of acute respiratory illness (probable symptomatic COVID-19 infection) and severity of the disease, including hospitalisation, in patients belonging to the high-risk group of COVID-19 infection, and the antibody response persists for quite a long time. A multi-centre study with a larger sample size will help to confirm the findings in this study. Clinical Trials Registry Clinical Trials Registry India (CTRI/2020/07/026668).
- 15 October 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (6) , 2205-2217
Open AccessEfficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial
Introduction Universal coverage of vaccines alone cannot be relied upon to protect at-risk populations in lower- and middle-income countries against the impact of the coronavirus disease 2019 (COVID-19) pandemic and newer variants. Live vaccines, including Bacillus Calmette–Guérin (BCG), are being studied for their effectiveness in reducing the incidence and severity of COVID-19 infection. Methods In this multi-centre quadruple-blind, parallel assignment randomised control trial, 495 high-risk group adults (aged 18–60 years) were randomised into BCG and placebo arms and followed up for 9 months from the date of vaccination. The primary outcome was the difference in the incidence of COVID-19 infection at the end of 9 months. Secondary outcomes included the difference in the incidence of severe COVID-19 infections, hospitalisation rates, intensive care unit stay, oxygen requirement and mortality at the end of 9 months. The primary analysis was done on an intention-to-treat basis, while safety analysis was done per protocol. Results There was no significant difference in the incidence rates of cartridge-based nucleic acid amplification test (CB-NAAT) positive COVID-19 infection [odds ratio (OR) 1.08, 95% confidence interval (CI) 0.54–2.14] in the two groups, but the BCG arm showed a statistically significant decrease in clinically diagnosed (symptomatic) probable COVID-19 infections (OR 0.38, 95% CI 0.20–0.72). Compared with the BCG arm, significantly more patients developed severe COVID-19 pneumonia (CB-NAAT positive) and required hospitalisation and oxygen in the placebo arm (six versus none; p = 0.03). One patient belonging to the placebo arm required intensive care unit (ICU) stay and died. BCG had a protective efficacy of 62% (95% CI 28–80%) for likely symptomatic COVID-19 infection. Conclusions BCG is protective in reducing the incidence of acute respiratory illness (probable symptomatic COVID-19 infection) and severity of the disease, including hospitalisation, in patients belonging to the high-risk group of COVID-19 infection, and the antibody response persists for quite a long time. A multi-centre study with a larger sample size will help to confirm the findings in this study. Clinical Trials Registry Clinical Trials Registry India (CTRI/2020/07/026668).
- 4 February 2021
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 115 (9) , 1019-1025
Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India
Background: The prevalence of anti-retroviral therapy (ART) failure is not uniform in India. In this study we attempted to determine the prevalence and risk factors of treatment failure among patients who were on ART for >1 y. Methods: We conducted an ambispective study from 2017 to 2019 in the All India Institute of Medical Sciences, New Delhi, India. Patients and their past medical records were examined to determine clinical, immunological and virological failure. Results: Among 301 enrolled patients, the majority was male (61.8%), with a mean age of 36.98±10.84 y. The prevalence of ART failure in our study was 10.63% (32/301). Clinical, immunological and virological failure rates were 1.66%, 10.63% and 5.65%, respectively. The maximum chance of failure was the tenofovir–lamivudine–nevirapine (33.3%) regimen followed by the stavudine–lamivudine–nevirapine (30.4%) regimen. Among the nucleoside reverse transcriptase inhibitors, a stavudine-based regimen had a significantly greater chance of failure (25.8%) compared with tenofovir (9.6%) and zidovudine (7.9%) regimens (p<0.005). Low baseline CD4 count and development of tuberculosis after ART initiation were significantly (p<0.05) associated with treatment failure in univariate analysis. Patients with a low peak CD4 count (adjusted odds ratio [AOR 4.26 {95% confidence interval 1.83 to 9.88}]) and who developed symptoms after ART initiation (AOR 3.77 [95% CI 1.47 to 9.69]) had significantly higher odds of treatment failure in the multivariate analysis (p<0.001). Conclusions: Early identification of risk factors by regular follow-up and selection of the proper ART regimen can reduce the rate of treatment failure.
- 4 February 2021
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 115 (9) , 1019-1025
Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India
Background: The prevalence of anti-retroviral therapy (ART) failure is not uniform in India. In this study we attempted to determine the prevalence and risk factors of treatment failure among patients who were on ART for >1 y. Methods: We conducted an ambispective study from 2017 to 2019 in the All India Institute of Medical Sciences, New Delhi, India. Patients and their past medical records were examined to determine clinical, immunological and virological failure. Results: Among 301 enrolled patients, the majority was male (61.8%), with a mean age of 36.98±10.84 y. The prevalence of ART failure in our study was 10.63% (32/301). Clinical, immunological and virological failure rates were 1.66%, 10.63% and 5.65%, respectively. The maximum chance of failure was the tenofovir–lamivudine–nevirapine (33.3%) regimen followed by the stavudine–lamivudine–nevirapine (30.4%) regimen. Among the nucleoside reverse transcriptase inhibitors, a stavudine-based regimen had a significantly greater chance of failure (25.8%) compared with tenofovir (9.6%) and zidovudine (7.9%) regimens (p<0.005). Low baseline CD4 count and development of tuberculosis after ART initiation were significantly (p<0.05) associated with treatment failure in univariate analysis. Patients with a low peak CD4 count (adjusted odds ratio [AOR 4.26 {95% confidence interval 1.83 to 9.88}]) and who developed symptoms after ART initiation (AOR 3.77 [95% CI 1.47 to 9.69]) had significantly higher odds of treatment failure in the multivariate analysis (p<0.001). Conclusions: Early identification of risk factors by regular follow-up and selection of the proper ART regimen can reduce the rate of treatment failure.
- Open Access
- 31 October 2019
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 13 (5) , 294-296
Pediatric case of Graham Little Piccardi Lassueur syndrome – A rare entity
Graham Little Piccardi Lassueur syndrome (GLPLS) is a rare dermatosis characterized by patchy cicatricial alopecia of scalp, rapidly developing keratosis pilaris like follicular papules over trunk and extremities, and noncicatricial loss of axillary and pubic hair. This syndrome which is mostly seen in middle aged post-menopausal females (between ages 30-70)has rarely ever been described in the pediatric age group. We report a case of a 15 year old girl presenting to us with this rare syndrome.
- 31 October 2019
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 13 (5) , 294-296
Open AccessPediatric case of Graham Little Piccardi Lassueur syndrome – A rare entity
Graham Little Piccardi Lassueur syndrome (GLPLS) is a rare dermatosis characterized by patchy cicatricial alopecia of scalp, rapidly developing keratosis pilaris like follicular papules over trunk and extremities, and noncicatricial loss of axillary and pubic hair. This syndrome which is mostly seen in middle aged post-menopausal females (between ages 30-70)has rarely ever been described in the pediatric age group. We report a case of a 15 year old girl presenting to us with this rare syndrome.
- Open Access
- 18 December 2016
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 15 (4) , 624-627
Primary Non-Hodgkin’s Orbital lymphoma of diffuse large B-cell type: a rare presentation
Primary Non-Hodgkin’s lymphoma of the orbit is a rare presentation and the diffuse large B-cell lymphoma (DLCL) type of histology is much less commoner than the mucosa associated lymphoid tissue (MALT) and follicular lymphoma. A 70 years female patient presented with palpable mass arising from right orbit and proptosis of the right eye. CT scan suggested homogenous enhancing soft tissue mass affecting right lacrimal region without any bony destruction. Biopsy confirmed it to be a case of Primary non-Hodgkin’s lymphoma of diffuse large B-cell type with strongly positive CD 20. She was given 6 cycles of chemotherapy with R-CHOP after surgery. The patient is now asymptomatic one year after the last cycle of the chemotherapy. Bangladesh Journal of Medical Science Vol.15(4) 2016 p.624-627
- 18 December 2016
- Published by Bangladesh Academy of Sciences in Bangladesh Journal of Medical Science
- Vol. 15 (4) , 624-627
Open AccessPrimary Non-Hodgkin’s Orbital lymphoma of diffuse large B-cell type: a rare presentation
Primary Non-Hodgkin’s lymphoma of the orbit is a rare presentation and the diffuse large B-cell lymphoma (DLCL) type of histology is much less commoner than the mucosa associated lymphoid tissue (MALT) and follicular lymphoma. A 70 years female patient presented with palpable mass arising from right orbit and proptosis of the right eye. CT scan suggested homogenous enhancing soft tissue mass affecting right lacrimal region without any bony destruction. Biopsy confirmed it to be a case of Primary non-Hodgkin’s lymphoma of diffuse large B-cell type with strongly positive CD 20. She was given 6 cycles of chemotherapy with R-CHOP after surgery. The patient is now asymptomatic one year after the last cycle of the chemotherapy. Bangladesh Journal of Medical Science Vol.15(4) 2016 p.624-627
- Open Access
- 26 October 2016
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 6 (2) , 130
Treatment of Autoimmune Haemolytic Anaemia with Hepatitis C Virus-A Real Challenge
- 26 October 2016
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 6 (2) , 130
Open AccessTreatment of Autoimmune Haemolytic Anaemia with Hepatitis C Virus-A Real Challenge